Protocol for Combined Analysis of FOXFIRE, SIRFLOX, and FOXFIRE-Global Randomized Phase III Trials of Chemotherapy +/- Selective Internal Radiation Therapy as First-Line Treatment for Patients With Metastatic Colorectal Cancer

Pradeep S Virdee, Joanna Moschandreas, Val Gebski, Sharon B Love, E Anne Francis, Harpreet S Wasan, Guy van Hazel, Peter Gibbs, Ricky A Sharma, Pradeep S Virdee, Joanna Moschandreas, Val Gebski, Sharon B Love, E Anne Francis, Harpreet S Wasan, Guy van Hazel, Peter Gibbs, Ricky A Sharma

Abstract

Background: In colorectal cancer (CRC), unresectable liver metastases are associated with a poor prognosis. The FOXFIRE (an open-label randomized phase III trial of 5-fluorouracil, oxaliplatin, and folinic acid +/- interventional radioembolization as first-line treatment for patients with unresectable liver-only or liver-predominant metastatic colorectal cancer), SIRFLOX (randomized comparative study of FOLFOX6m plus SIR-Spheres microspheres versus FOLFOX6m alone as first-line treatment in patients with nonresectable liver metastases from primary colorectal carcinoma), and FOXFIRE-Global (assessment of overall survival of FOLFOX6m plus SIR-Spheres microspheres versus FOLFOX6m alone as first-line treatment in patients with nonresectable liver metastases from primary colorectal carcinoma in a randomized clinical study) clinical trials were designed to evaluate the efficacy and safety of combining first-line chemotherapy with selective internal radiation therapy (SIRT) using yttrium-90 resin microspheres, also called transarterial radioembolization.

Objective: The aim of this analysis is to prospectively combine clinical data from 3 trials to allow adequate power to evaluate the impact of chemotherapy with SIRT on overall survival.

Methods: Eligible patients are adults with histologically confirmed CRC and unequivocal evidence of liver metastases which are not treatable by surgical resection or local ablation with curative intent at the time of study entry. Patients may also have limited extrahepatic metastases. Final analysis will take place when all participants have been followed up for a minimum of 2 years.

Results: Efficacy and safety estimates derived using individual participant data (IPD) from SIRFLOX, FOXFIRE, and FOXFIRE-Global will be pooled using 2-stage prospective meta-analysis. Secondary outcome measures include progression-free survival (PFS), liver-specific PFS, health-related quality of life, response rate, resection rate, and adverse event profile. The large study population will facilitate comparisons of low frequency adverse events and allow for more robust safety analyses. The potential treatment benefit in those patients who present with disease confined to the liver will be investigated using 1-stage IPD meta-analysis. Efficacy will be analyzed on an intention-to-treat basis.

Conclusions: This analysis will assess the impact of SIRT combined with chemotherapy on overall survival in the first-line treatment of metastatic CRC. If positive, the results will change the standard of care for this disease.

Trial registration: FOXFIRE ISRCTN Registry ISRCTN83867919; http://www.isrctn.com/ISRCTN83867919 (Archived by WebCite at http://www.webcitation.org/6oN7axrvA). SIRFLOX ClinicalTrials.gov NCT00724503; https://ichgcp.net/clinical-trials-registry/NCT00724503 (Archived by WebCite at http://www.webcitation.org/6oN7lEGbD). FOXFIRE-Global ClinicalTrials.gov NCT01721954; https://ichgcp.net/clinical-trials-registry/NCT01721954 (Archived by WebCite at http://www.webcitation.org/ 6oN7vvQvG).

Keywords: colorectal neoplasms; liver; meta-analysis; neoplasm metastasis; radiation oncology; survival analysis.

Conflict of interest statement

Conflicts of Interest: RAS has received research funding, honoraria, and consultancy fees from Sirtex Medical Ltd. PG has received honoraria from Sirtex for participation in advisory boards and for giving presentations. VG and GVH have received compensation for participation in advisory committees from Sirtex. PSV, JM, HSW, EAF, and SBL declare no competing interests.

©Pradeep S Virdee, Joanna Moschandreas, Val Gebski, Sharon B Love, E Anne Francis, Harpreet S Wasan, Guy van Hazel, Peter Gibbs, Ricky A Sharma. Originally published in JMIR Research Protocols (http://www.researchprotocols.org), 28.03.2017.

Figures

Figure 1
Figure 1
Schema for the FOXFIRE, SIRFLOX, and FOXFIRE-Global trials.

References

    1. Surveillance, Epidemiology, and End Results Stat Fact Sheets: Colon and Rectum Cancer, 2003-2009. 2013. [2016-12-15]. .
    1. Abbas S, Lam V, Hollands M. Ten-year survival after liver resection for colorectal metastases: systematic review and meta-analysis. ISRN Oncol. 2011 doi: 10.5402/2011/763245. doi: 10.5402/2011/763245.
    1. Helling TS, Martin M. Cause of death from liver metastases in colorectal cancer. Ann Surg Oncol. 2014 Feb;21(2):501–506. doi: 10.1245/s10434-013-3297-7.
    1. Rothbarth J, van de Velde CJH. Treatment of liver metastases of colorectal cancer. Ann Oncol. 2005;16 Suppl 2:ii144–ii149. doi: 10.1093/annonc/mdi702.
    1. Berber E, Pelley R, Siperstein AE. Predictors of survival after radiofrequency thermal ablation of colorectal cancer metastases to the liver: a prospective study. J Clin Oncol. 2005 Mar 01;23(7):1358–1364. doi: 10.1200/JCO.2005.12.039.
    1. Navarra G, Ayav A, Weber J, Jensen SL, Smadga C, Nicholls JP, Habib NA, Jiao LR. Short- and long-term results of intraoperative radiofrequency ablation of liver metastases. Int J Colorectal Dis. 2005 Nov;20(6):521–528. doi: 10.1007/s00384-005-0743-4.
    1. Van Cutsem E, Nordlinger B, Adam R, Köhne C, Pozzo C, Poston G, Ychou M, Rougier P, European Colorectal Metastases Treatment Group Towards a pan-European consensus on the treatment of patients with colorectal liver metastases. Eur J Cancer. 2006 Sep;42(14):2212–2221. doi: 10.1016/j.ejca.2006.04.012.
    1. Jones RP, Poston GJ. Resection of liver metastases in colorectal cancer in the era of expanding systemic therapy. Annu Rev Med. 2016 Sep 28; doi: 10.1146/annurev-med-062415-093510.
    1. Alberts SR, Horvath WL, Sternfeld WC, Goldberg RM, Mahoney MR, Dakhil SR, Levitt R, Rowland K, Nair S, Sargent DJ, Donohue JH. Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study. J Clin Oncol. 2005 Dec 20;23(36):9243–9249. doi: 10.1200/JCO.2005.07.740.
    1. Folprecht G, Grothey A, Alberts S, Raab H, Köhne C. Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. Ann Oncol. 2005 Aug;16(8):1311–1319. doi: 10.1093/annonc/mdi246.
    1. Nicolay NH, Berry DP, Sharma RA. Liver metastases from colorectal cancer: radioembolization with systemic therapy. Nat Rev Clin Oncol. 2009 Dec;6(12):687–697. doi: 10.1038/nrclinonc.2009.165.
    1. Wang LM, Jani AR, Hill EJ, Sharma RA. Anatomical basis and histopathological changes resulting from selective internal radiotherapy for liver metastases. J Clin Pathol. 2013 Mar;66(3):205–211. doi: 10.1136/jclinpath-2012-201231.
    1. Dutton SJ, Kenealy N, Love SB, Wasan HS, Sharma RA, FOXFIRE Protocol Development Group and the NCRI Colorectal Clinical Study Group FOXFIRE protocol: an open-label, randomised, phase III trial of 5-fluorouracil, oxaliplatin and folinic acid (OxMdG) with or without interventional Selective Internal Radiation Therapy (SIRT) as first-line treatment for patients with unresectable liver-only or liver-dominant metastatic colorectal cancer. BMC Cancer. 2014 Jul 09;14:497. doi: 10.1186/1471-2407-14-497.
    1. Gibbs P, Gebski V, Van Buskirk M, Thurston K, Cade DN, Van Hazel GA. Selective Internal Radiation Therapy (SIRT) with yttrium-90 resin microspheres plus standard systemic chemotherapy regimen of FOLFOX versus FOLFOX alone as first-line treatment of non-resectable liver metastases from colorectal cancer: the SIRFLOX study. BMC Cancer. 2014 Dec 01;14:897. doi: 10.1186/1471-2407-14-897.
    1. van Hazel GA, Heinemann V, Sharma NK, Findlay MPN, Ricke J, Peeters M, Perez D, Robinson BA, Strickland AH, Ferguson T, Rodríguez J, Kröning H, Wolf I, Ganju V, Walpole E, Boucher E, Tichler T, Shacham-Shmueli E, Powell A, Eliadis P, Isaacs R, Price D, Moeslein F, Taieb J, Bower G, Gebski V, Van Buskirk M, Cade DN, Thurston K, Gibbs P. SIRFLOX: randomized phase III trial comparing first-line mFOLFOX6 (plus or minus bevacizumab) versus mFOLFOX6 (plus or minus bevacizumab) plus selective internal radiation therapy in patients with metastatic colorectal cancer. J Clin Oncol. 2016 May 20;34(15):1723–1731. doi: 10.1200/JCO.2015.66.1181.
    1. Gray B, Van Hazel G, Hope M, Burton M, Moroz P, Anderson J, Gebski V. Randomised trial of SIR-Spheres plus chemotherapy versus chemotherapy alone for treating patients with liver metastases from primary large bowel cancer. Ann Oncol. 2001 Dec;12(12):1711–1720.
    1. Shimizu T, Satoh T, Tamura K, Ozaki T, Okamoto I, Fukuoka M, Nakagawa K. Oxaliplatin/fluorouracil/leucovorin (FOLFOX4 and modified FOLFOX6) in patients with refractory or advanced colorectal cancer: post-approval Japanese population experience. Int J Clin Oncol. 2007 Jun;12(3):218–223. doi: 10.1007/s10147-007-0658-x.
    1. Braun MS, Adab F, Bradley C, McAdam K, Thomas G, Wadd NJ, Rea D, Philips R, Twelves C, Bozzino J, MacMillan C, Saunders MP, Counsell R, Anderson H, McDonald A, Stewart J, Robinson A, Davies S, Richards FJ, Seymour MT. Modified de Gramont with oxaliplatin in the first-line treatment of advanced colorectal cancer. Br J Cancer. 2003 Oct 06;89(7):1155–1158. doi: 10.1038/sj.bjc.6601237. doi: 10.1038/sj.bjc.6601237.
    1. Allegra CJ, Yothers G, O'Connell MJ, Sharif S, Petrelli NJ, Colangelo LH, Atkins JN, Seay TE, Fehrenbacher L, Goldberg RM, O'Reilly S, Chu L, Azar CA, Lopa S, Wolmark N. Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08. J Clin Oncol. 2011 Jan 01;29(1):11–16. doi: 10.1200/JCO.2010.30.0855.
    1. Clary BM, Grothey A, Kopetz S, Marsh RDW. Systemic cytotoxic and biologic therapies for colorectal cancer liver metastases: expert consensus statement. HPB (Oxford) 2013 Feb;15(2):116–118. doi: 10.1111/j.1477-2574.2012.00598.x.
    1. Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, Bechstein WO, Primrose JN, Walpole ET, Finch-Jones M, Jaeck D, Mirza D, Parks RW, Mauer M, Tanis E, Van Cutsem CE, Scheithauer W, Gruenberger T, EORTC Gastro-Intestinal Tract Cancer Group. Cancer UK. Arbeitsgruppe Lebermetastasen und tumoren in der Chirurgischen Arbeitsgemeinschaft Onkologie (ALM-CAO) Australasian Gastro-Intestinal Trials Group (AGITG) Fédération Francophone de Cancérologie Digestive (FFCD) Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. Lancet Oncol. 2013 Nov;14(12):1208–1215. doi: 10.1016/S1470-2045(13)70447-9.
    1. Bokemeyer C, Van Cutsem E, Rougier P, Ciardiello F, Heeger S, Schlichting M, Celik I, Köhne CH. Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials. Eur J Cancer. 2012 Jul;48(10):1466–1475. doi: 10.1016/j.ejca.2012.02.057.
    1. Ruers T, Punt C, Van Coevorden F, Pierie JPEN, Borel-Rinkes I, Ledermann JA, Poston G, Bechstein W, Lentz MA, Mauer M, Van Cutsem E, Lutz MP, Nordlinger B, EORTC Gastro-Intestinal Tract Cancer Group. Arbeitsgruppe Lebermetastasen und tumoren in der Chirurgischen Arbeitsgemeinschaft Onkologie (ALM-CAO) National Cancer Research Institute Colorectal Clinical Study Group (NCRI CCSG) Radiofrequency ablation combined with systemic treatment versus systemic treatment alone in patients with non-resectable colorectal liver metastases: a randomized EORTC Intergroup phase II study (EORTC 40004) Ann Oncol. 2012 Oct;23(10):2619–2626. doi: 10.1093/annonc/mds053.
    1. Ruers T, Cornelis J, Punt C, Van Coevorden F, Pierie J, Rinkes I, Ledermann J, Poston G, Bechstein W, Lentz M, Mauer M, Van Cutsem E, Lutz M, Nordlinger B. Radiofrequency ablation (RFA) combined with chemotherapy for unresectable colorectal liver metastases (CRC LM): Long-term survival results of a randomized phase II study of the EORTC-NCRI CCSG-ALM Intergroup 40004 (CLOCC) J Clin Oncol. 2015;33(Suppl):A3501.
    1. Tierney JF, Vale C, Riley R, Smith CT, Stewart L, Clarke M, Rovers M. Individual participant data (IPD) meta-analyses of randomised controlled trials: guidance on their use. PLoS Med. 2015 Jul;12(7):e1001855. doi: 10.1371/journal.pmed.1001855.
    1. Debray TPA, Moons KGM, Abo-Zaid GMA, Koffijberg H, Riley RD. Individual participant data meta-analysis for a binary outcome: one-stage or two-stage? PLoS One. 2013;8(4):e60650. doi: 10.1371/journal.pone.0060650.
    1. Stewart GB, Altman DG, Askie LM, Duley L, Simmonds MC, Stewart LA. Statistical analysis of individual participant data meta-analyses: a comparison of methods and recommendations for practice. PLoS One. 2012;7(10):e46042. doi: 10.1371/journal.pone.0046042.

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj